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LETTERS TO THE EDITOR
Immunosuppressive Treatment in Familial
Dilated Cardiomyopathy With Biopsy-proven
Intramyocardial Inflammation?
In a recent issue of the Journal, Mahon et al. (1) added substan-
tially to the pathogenesis of familial dilated cardiomyopathy
(DCM), elucidating that intramyocardial inflammation, as as-
sessed by immunohistochemical quantification of CD3
T-lymphocytes and abundance of endothelial cell adhesion mole-
cule expression (ICAM-1 and HLA-DR), is significantly present
in asymptomatic individuals with left ventricular enlargement and
who are relatives of patients with familial DCM. Their report
confirms previous findings on anticardiac autoimmunity in familial
DCM, such as autoantibodies (2) and the HLA type DR4-linked
predisposition (3). The first successful immunosuppressive study in
DCM, demonstrating beneficial long-term hemodynamic effects
over a two-year follow-up period, was based on the immunohis-
tochemical diagnosis of inflammatory cardiomyopathy (i.e., HLA
abundance) (4). In contrast, preliminary data by Chimenti et al. (5)
elucidated that only patients with biopsy-proven absence of viral
persistence will benefit from such immunosuppressive treatment.
Given the reported absence of enteroviral, adenoviral, and
cytomegaloviral genome in familial DCM (6), would the investi-
gators consider immunosuppressive treatment to prevent disease
progression in patients with established familial DCM and in their
asymptomatic relatives who have left ventricular enlargement?
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REPLY
We thank Dr. Noutsias and colleagues for their comments
regarding our report (1). Although dilated cardiomyopathy
(DCM) is classified as idiopathic, familial/genetic, viral and/or
immune (2), in the real world we lack consensus diagnostic criteria
for viral and/or immune DCM. In relation to the key question, as
to whether immunosuppression is indicated in DCM patients and
their relatives with left ventricular enlargement (LVE) (2), we
would suggest that the rational base is the establishment of
accepted consensus diagnostic criteria. This should set the ground-
work for future controlled studies of immunosuppressive therapy in
DCM. We agree with Dr. Noutsias and co-workers that autoim-
mune DCM is defined by lack of viral genome by polymerase chain
reaction (PCR) and myocardial inflammation by immunohisto-
chemistry. Although the study by Wojnicz et al. (3) has shown
beneficial hemodynamic effects of immunosuppression after two-
years, it failed to show a favorable effect on mortality, possibly
because it was statistically underpowered. Conversely, the IMAC
trial failed to demonstrate efficacy in recent-onset DCM and
myocarditis, but patients were not stratified in terms of pathogen-
esis (4). Thus, multicenter studies enrolling adequate numbers of
patients using consensus criteria for viral versus immune inflam-
mation are needed. Meanwhile, on the basis of the Polish study (3)
a short course of immunosuppression may be considered in
patients with established inflammatory DCM, with no replicating
virus. In these patients the prognosis remains poor, and the
potential benefit of halting disease progression is high.
It is, however, premature to administer immunosuppression for
asymptomatic LVE relatives with myocardial inflammation. Al-
though such therapy has the potential to prevent disease progres-
sion, the absolute risk of progression in LVE needs to be
quantified. Data from an initial cohort demonstrated progression
in 27% of subjects over three years (5), but longer follow-up in a
larger cohort is required. Second, five-year follow-up has revealed
that serum detection of cardiac-specific antibodies (6) with or
without LVE at baseline is also a noninvasive predictor of disease
progression (7). The clinical challenge is to identify more accu-
rately, ideally with noninvasive markers, asymptomatic relatives at
risk. We believe it is necessary to obtain such data before
considering a potentially deleterious therapy such as immunosup-
pression in asymptomatic relatives with preserved systolic function.
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